Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data

Autor: Caroline Arber, Gabriela Baerlocher, Yves Chalandon, Michael Daskalakis, Michel Duchosal, Martin Fehr, Sabine Gerull, Tayfun Güngör, Gayathri Nair, Thomas Pabst, Jakob R. Passweg, Barbara Piccolruaz, Christoph Renner, Axel Ruefer, Dominik Schneidawind, Georg Stüssi, Sacha Zeerleder, Jörg P. Halter

Publikováno v: Swiss Medical Weekly, Vol 154, Iss 10 (2024)

No abstract available.

Externí odkaz: https://doaj.org/article/1a08507158c34aa0be6c05c66d9e61ff

The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14

Autor: Beatrice Drexler, Jakob R. Passweg, Alexandar Tzankov, Martin Bigler, Alexandre PA Theocharides, Nathan Cantoni, Peter Keller, Georg Stussi, Axel Ruefer, Rudolf Benz, Geneviève Favre, Pontus Lundberg, Ronny Nienhold, Andrea Fuhrer, Christine Biaggi, Markus G. Manz, Mario Bargetzi, Simon Mendez-Ferrer, Radek C. Skoda

Publikováno v: Haematologica, Vol 104, Iss 4 (2019)

The β-3 sympathomimetic agonist BRL37344 restored nestin-positive cells within the stem cell niche, and thereby normalized blood counts and improved myelofibrosis in a mouse model of JAK2-V617F-positive myeloproliferative neoplasms. We therefore tes

Externí odkaz: https://doaj.org/article/8479aa021716446aad1f99447b3fef97

Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine

Autor: Nicolas Bonadies, Kristina Stojkov, Helena Simeunovic, Ioannis Chanias, Ulrike Bacher, Alicia Rovó, Georg Stuessi, Gregor Stehle, Annatina Schnegg-Kaufmann, Stefan Balabanov, Axel Ruefer, Ramanjaneyulu Allam, Linet M. Njue, Michael Daskalakis, Rudolf Benz, Adrian Schmidt, Marcel Adler, Naomi Porret, Tata Nageswara Rao

Publikováno v: Cancers
Cancers, Vol 13, Iss 3296, p 3296 (2021)
Chanias, Ioannis; Stojkov, Kristina; Stehle, Gregor Th.; Daskalakis, Michael; Simeunovic, Helena; Njue, Linet Muthoni; Schnegg-Kaufmann, Annatina S.; Porret, Naomi A.; Allam, Ramanjaneyulu; Tata, Nageswara Rao; Benz, Rudolf; Ruefer, Axel; Schmidt, Adrian; Adler, Marcel; Rovo, Alicia; Balabanov, Stefan; Stuessi, Georg; Bacher, Ulrike; Bonadies, Nicolas (2021). Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine. Cancers, 13(13) MDPI AG 10.3390/cancers13133296

Simple Summary With demographic ageing, improved cancer survivorship and increased diagnostic sensitivity, incident cases of patients with Myelodysplastic Syndromes (MDS) are continuously rising, leading to a relevant impact on health care resources.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fbf995eaefba52948ea69211a04929c
https://www.zora.uzh.ch/id/eprint/207120/

Autologous stem cell transfusions on multiple days in patients with multiple myeloma-Does it matter?

Autor: Daniel Betticher, Urban Novak, Ulrike Bacher, Barbara Jeker, Thomas Pabst, Thomas Egger, Sebastian Moser, Axel Ruefer, Behrouz Mansouri Taleghani

Publikováno v: Moser, Sebastian; Bacher, Vera Ulrike; Jeker, Barbara; Mansouri Taleghani, Behrouz; Betticher, Daniel; Ruefer, Axel; Egger, Thomas; Novak, Urban; Pabst, Thomas (2019). Autologous stem cell transfusions on multiple days in patients with multiple myeloma - does it matter? Hematological oncology, 37(5), pp. 649-651. Wiley 10.1002/hon.2673

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2b5cff3e8fc8148bc8f49a18189a036
https://pubmed.ncbi.nlm.nih.gov/31483507

The sympathomimetic agonist mirabegron did not lower JAK2 -V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14

Autor: Nathan Cantoni, Axel Ruefer, Ronny Nienhold, Pontus Lundberg, Beatrice Drexler, Georg Stussi, Martin Bigler, Mario Bargetzi, Andrea Fuhrer, Radek C. Skoda, Jakob Passweg, Rudolf Benz, Markus G. Manz, Alexandre Theocharides, Alexandar Tzankov, Peter Keller, Geneviève Favre, Simón Méndez-Ferrer, Christine Biaggi

Publikováno v: Haematologica

The β-3 sympathomimetic agonist BRL37344 restored nestin-positive cells within the stem cell niche, and thereby normalized blood counts and improved myelofibrosis in a mouse model of JAK2-V617F-positive myeloproliferative neoplasms. We therefore tes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fec5211c6fbef0637b39659ec07986d0